Cost-effectiveness of using recombinant activated factor VII as an off-label rescue treatment for critical bleeding requiring massive transfusion.

@article{Ho2012CosteffectivenessOU,
  title={Cost-effectiveness of using recombinant activated factor VII as an off-label rescue treatment for critical bleeding requiring massive transfusion.},
  author={Kwok M Ho and Edward Litton},
  journal={Transfusion},
  year={2012},
  volume={52 8},
  pages={
          1696-702
        }
}
BACKGROUND Recombinant activated factor VII (rFVIIa) is widely used as an off-label rescue treatment for patients with nonhemophilic critical bleeding. STUDY DESIGN AND METHODS Using data from the intensive care unit, transfusion service, and death registry, the long-term survival after using rFVIIa and the associated cost per life-year gained in a consecutive cohort of patients with critical bleeding requiring massive transfusion (≥ 10 red blood cell [RBC] units in 24 hr) were assessed… CONTINUE READING